Market closed

Axsome Therapeutics/$AXSM

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Axsome Therapeutics

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Ticker

$AXSM

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

New York, United States

Employees

607

Website

www.axsome.com

AXSM Metrics

BasicAdvanced

$4.1B

-

-$6.53

1.01 -

Price and volume

Market cap

$4.1B

Beta

1.01

52-week high

$99.50

52-week low

$64.11

Average daily volume

750K

Financial strength

Current ratio

2.442

Quick ratio

2.301

Long term debt to equity

203.872

Total debt to equity

207.001

Interest coverage (TTM)

-48.58%

Management effectiveness

Return on assets (TTM)

-26.44%

Return on equity (TTM)

-171.61%

Valuation

Price to revenue (TTM)

11.902

Price to book

44.11

Price to tangible book (TTM)

126.65

Price to free cash flow (TTM)

-30.329

Growth

Revenue change (TTM)

51.47%

Earnings per share change (TTM)

43.92%

3-year earnings per share growth (CAGR)

24.97%

What the Analysts think about AXSM

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.

AXSM Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

AXSM Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

AXSM News

AllArticlesVideos

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Seeking Alpha·2 weeks ago

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

Benzinga·2 weeks ago

Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study

Reuters·2 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AXSM

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Axsome Therapeutics stock?

Axsome Therapeutics (AXSM) has a market cap of $4.1B as of January 15, 2025.

What is the P/E ratio for Axsome Therapeutics stock?

The price to earnings (P/E) ratio for Axsome Therapeutics (AXSM) stock is 0 as of January 15, 2025.

Does Axsome Therapeutics stock pay dividends?

No, Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Axsome Therapeutics dividend payment date?

Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders.

What is the beta indicator for Axsome Therapeutics?

Axsome Therapeutics (AXSM) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.